Public Profile

United Therapeutics

United Therapeutics Corporation, commonly referred to as United Therapeutics, is a pioneering biotechnology company headquartered in the United States. Founded in 1996, the company has established itself as a leader in the development of innovative therapies for patients with chronic and life-threatening conditions, particularly in the field of pulmonary arterial hypertension (PAH). With a strong operational presence across North America and Europe, United Therapeutics focuses on creating unique, life-saving products, including its flagship medications like Remodulin and Tyvaso. These therapies are distinguished by their advanced delivery systems and commitment to improving patient quality of life. Recognised for its significant contributions to the biopharmaceutical industry, United Therapeutics has achieved notable milestones, including the successful development of organ preservation technologies. The company continues to solidify its market position through ongoing research and a dedication to addressing unmet medical needs.

DitchCarbon Score

How does United Therapeutics's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

18

Industry Average

Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

19

Industry Benchmark

United Therapeutics's score of 18 is lower than 77% of the industry. This can give you a sense of how well the company is doing compared to its peers.

23%

United Therapeutics's reported carbon emissions

United Therapeutics, headquartered in the US, currently does not have publicly available carbon emissions data or specific reduction targets. As a result, there are no reported figures for their Scope 1, 2, or 3 emissions. However, the company is likely engaged in various climate commitments and initiatives typical of the pharmaceutical industry, focusing on sustainability and reducing environmental impact. Without specific data or targets, it is challenging to provide a detailed overview of their carbon emissions and climate commitments.

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. United Therapeutics's primary industry is Health and social work services (85), which is low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. United Therapeutics is headquartered in US, which has a rank of low, indicating low grid carbon intensity.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

United Therapeutics is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero

Was this information valuable to you?

Similar Organizations

Celgene Corporation

US
Chemicals nec
Updated about 2 months ago
DitchCarbon Score

Bayer Pharma AG

DE
Chemicals nec
Updated 2 months ago
DitchCarbon Score

Gilead Sciences

US
Research and development services (73)
Updated 9 days ago

Actelion Ltd

CH
Chemicals nec
Updated about 2 months ago
DitchCarbon Score

Celanese

US
Chemicals nec
Updated 14 days ago

Genentech

US
Research and development services (73)
Updated 5 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers